Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

被引:0
|
作者
Armstrong, April W. [1 ]
Soliman, Ahmed M. [2 ]
Gisondi, Paolo [3 ]
Fang, Siran [2 ]
Patel, Manish [2 ]
Strober, Bruce [4 ,5 ]
机构
[1] Univ Southern Calif, Keck Sch Med, Dept Dermatol, 1450 San Pablo St 5400, Los Angeles, CA 90033 USA
[2] AbbVie Inc, N Chicago, IL USA
[3] Univ Verona, Dept Med, Sect Dermatol & Venereol, Verona, Italy
[4] Yale Univ, Dept Dermatol, New Haven, CT USA
[5] Cent Connecticut Dermatol, Cromwell, CT USA
关键词
Deucravacitinib; Matching-adjusted indirect comparison; Plaque psoriasis; Risankizumab; ADALIMUMAB;
D O I
10.1007/s13555-024-01293-y
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
IntroductionDespite advancements in the treatment of psoriasis (PsO), there are few head-to-head studies assessing comparative effectiveness of the newest therapies approved to treat PsO. Our objective was to assess the comparative clinical effectiveness of risankizumab and deucravacitinib in patients with moderate-to-severe PsO.MethodsThis placebo-anchored matching-adjusted indirect comparison (MAIC) analysis utilized data from UltIMMa-1/2 risankizumab and POETYK PSO-1/2 deucravacitinib trials. Individual patient data from UltiMMA-1/2 were weighted via propensity score to match POETYK PSO-1/2 published summary data. Rate differences between risankizumab and deucravacitinib were assessed for Psoriasis Area and Severity Index (PASI) 75/90/100, the Static Physician Global Assessment (sPGA = 0 or 0/1), and the Dermatology Life Quality Index (DLQI) 0/1.ResultsAt 16 weeks, risankizumab-treated patients demonstrated statistically significantly higher rates of skin clearance and greater improvement in quality of life (QoL) compared to those treated with deucravacitinib. Across all outcomes, risankizumab demonstrated a lower number needed to treat compared to deucravacitinib. Limitations are potential bias due to unobserved/unmeasurable differences and limited generalizability of the results.ConclusionsThis indirect comparison demonstrates that risankizumab has higher rates of skin clearance and greater improvements in QoL than deucravacitinib. This study will help inform healthcare providers in their treatment and management strategy of PsO.
引用
收藏
页码:3071 / 3081
页数:11
相关论文
共 50 条
  • [31] Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis
    Li, Wendy
    Ghamrawi, Rima
    Haidari, Wasim
    Feldman, Steven R.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (04) : 380 - 387
  • [32] A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF UPADACITINIB VERSUS TOFACITINIB IN CSDMARD-IR PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA)
    Edwards, Christopher
    Sawant, Ruta
    Du, Ella
    Cammarota, Jordan
    Tang, Patrick
    Garg, Vishvas
    Friedman, Alan
    Betts, Keith
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 358 - 358
  • [33] Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
    Blair, Hannah A.
    DRUGS, 2020, 80 (12) : 1235 - 1245
  • [34] Safety in numbers: risankizumab for moderate-to-severe psoriasis
    Mirali, S.
    Fabusiwa, K.
    Linos, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 394 - 395
  • [35] Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis
    Galluzzo, Marco
    Vellucci, Laura
    Marcelli, Lorenzo
    Paganini, Claudia
    Bianchi, Luca
    Talamonti, Marina
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (09) : 981 - 988
  • [36] High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis
    Gooderham, M.
    Lebwohl, M.
    Gordon, K.
    Wu, T.
    Photowala, H.
    Bachelez, H.
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (04) : E30 - E31
  • [37] High and durable clearance through 52 weeks of risankizumab treatment in patients with moderate-to-severe plaque psoriasis
    Gooderham, M.
    Lebwohl, M.
    Gordon, K.
    Wu, T.
    Photowala, H.
    Bachelez, H.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 20
  • [38] Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Kim Rand
    Juan Manuel Ramos-Goñi
    Bülent Akmaz
    Laia Solé-Feu
    José-Carlos Armario-Hita
    Dermatology and Therapy, 2024, 14 (1) : 183 - 185
  • [39] Biological treatments for moderate-to-severe psoriasis: indirect comparison
    Galvan-Banqueri, M.
    Marin Gil, R.
    Santos Ramos, B.
    Bautista Paloma, F. J.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (02) : 121 - 130
  • [40] Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments
    Crowley, Jeffrey
    Hong, Chih-Ho
    Gooderham, Melinda
    Kokolakis, Georgios
    Photowala, Huzefa
    Rubant, Simone
    Zhan, Tianyu
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB82 - AB82